561 related articles for article (PubMed ID: 20877357)
61. Mathematical Approach to Differentiate Spontaneous and Induced Evolution to Drug Resistance During Cancer Treatment.
Greene JM; Gevertz JL; Sontag ED
JCO Clin Cancer Inform; 2019 Apr; 3():1-20. PubMed ID: 30969799
[TBL] [Abstract][Full Text] [Related]
62. Drug resistance, epigenetics, and tumor cell heterogeneity.
Hoey T
Sci Transl Med; 2010 Apr; 2(28):28ps19. PubMed ID: 20410528
[TBL] [Abstract][Full Text] [Related]
63. Natural and Chemotherapy-Induced Clonal Evolution of Tumors.
Ibragimova MK; Tsyganov MM; Litviakov NV
Biochemistry (Mosc); 2017 Apr; 82(4):413-425. PubMed ID: 28371598
[TBL] [Abstract][Full Text] [Related]
64. Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance.
Marusyk A; Janiszewska M; Polyak K
Cancer Cell; 2020 Apr; 37(4):471-484. PubMed ID: 32289271
[TBL] [Abstract][Full Text] [Related]
65. Interplay of Darwinian Selection, Lamarckian Induction and Microvesicle Transfer on Drug Resistance in Cancer.
Álvarez-Arenas A; Podolski-Renic A; Belmonte-Beitia J; Pesic M; Calvo GF
Sci Rep; 2019 Jun; 9(1):9332. PubMed ID: 31249353
[TBL] [Abstract][Full Text] [Related]
66. Tracking the evolution of cancer cell populations through the mathematical lens of phenotype-structured equations.
Lorenzi T; Chisholm RH; Clairambault J
Biol Direct; 2016 Aug; 11(1):43. PubMed ID: 27550042
[TBL] [Abstract][Full Text] [Related]
67. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?
Arnedos M; Vielh P; Soria JC; Andre F
J Pathol; 2014 Jan; 232(2):274-82. PubMed ID: 24114621
[TBL] [Abstract][Full Text] [Related]
68. Somatic alterations as the basis for resistance to targeted therapies.
Blair BG; Bardelli A; Park BH
J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
[TBL] [Abstract][Full Text] [Related]
69. Evolutionary dynamics of intratumor heterogeneity.
Iwasa Y; Michor F
PLoS One; 2011 Mar; 6(3):e17866. PubMed ID: 21479218
[TBL] [Abstract][Full Text] [Related]
70. Lung Cancer Heterogeneity and New Strategies for Drug Therapy.
Wang DC; Wang W; Zhu B; Wang X
Annu Rev Pharmacol Toxicol; 2018 Jan; 58():531-546. PubMed ID: 28977762
[TBL] [Abstract][Full Text] [Related]
71. Mechanisms of acquired resistance to targeted cancer therapies.
Lackner MR; Wilson TR; Settleman J
Future Oncol; 2012 Aug; 8(8):999-1014. PubMed ID: 22894672
[TBL] [Abstract][Full Text] [Related]
72. Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation.
Chisholm RH; Lorenzi T; Clairambault J
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt B):2627-45. PubMed ID: 27339473
[TBL] [Abstract][Full Text] [Related]
73. Cancer: evolution within a lifetime.
Gerlinger M; McGranahan N; Dewhurst SM; Burrell RA; Tomlinson I; Swanton C
Annu Rev Genet; 2014; 48():215-36. PubMed ID: 25292359
[TBL] [Abstract][Full Text] [Related]
74. Cancer and natural selection.
Fillon M
J Natl Cancer Inst; 2012 Dec; 104(23):1773-4. PubMed ID: 23213180
[No Abstract] [Full Text] [Related]
75. Evolutionary triage governs fitness in driver and passenger mutations and suggests targeting never mutations.
Gatenby RA; Cunningham JJ; Brown JS
Nat Commun; 2014 Nov; 5():5499. PubMed ID: 25407411
[TBL] [Abstract][Full Text] [Related]
76. Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure.
Lippert TH; Ruoff HJ; Volm M
Arzneimittelforschung; 2008; 58(6):261-4. PubMed ID: 18677966
[TBL] [Abstract][Full Text] [Related]
77. Cancer in light of experimental evolution.
Sprouffske K; Merlo LM; Gerrish PJ; Maley CC; Sniegowski PD
Curr Biol; 2012 Sep; 22(17):R762-71. PubMed ID: 22975007
[TBL] [Abstract][Full Text] [Related]
78. Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing.
Kohsaka S; Petronczki M; Solca F; Maemondo M
Future Oncol; 2019 Feb; 15(6):637-652. PubMed ID: 30404555
[TBL] [Abstract][Full Text] [Related]
79. Intratumor heterogeneity in evolutionary models of tumor progression.
Durrett R; Foo J; Leder K; Mayberry J; Michor F
Genetics; 2011 Jun; 188(2):461-77. PubMed ID: 21406679
[TBL] [Abstract][Full Text] [Related]
80. Cancer drug resistance: A fleet to conquer.
Hussain S; Singh A; Nazir SU; Tulsyan S; Khan A; Kumar R; Bashir N; Tanwar P; Mehrotra R
J Cell Biochem; 2019 Sep; 120(9):14213-14225. PubMed ID: 31037763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
